ALS is linked to toxic TDP-43 protein clumps. A new strategy targets a specific protein region. A small molecule, XL20, prevents clumping, reducing nerve damage in human cells. XL20 extended survival ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that affects people differently, with ALS prognosis varying considerably from one person to another. The condition gradually ...

An expanded access program for Qalsody in ALS patients was feasible and well-tolerated. The program provided Qalsody to 11 ALS patients ineligible for trials. A mixed funding model, including ...

I walked with our dog, Comet, on a trail in the woods behind our house. The woods felt cool out of the hot sun. Light filtered through the trees overhead as I breathed in the rich smell of summer ...

Australian data links over 10% of ALS cases to known genetic mutations. The SALSA-SGC consortium collects data to understand ALS causes and progression. The project brings together seven major motor ...

A co-designed robotic glove restored grip and independent feeding for a man with severe ALS. The soft, wearable device uses inflatable cushions, controlled by residual muscle signals. This low-cost ...

Neuralink tested a brain implant approach that threads electrodes through the dura without cutting it open. The company says ...

A less invasive brain-computer interface is being developed to help people with impaired speech, including ALS, communicate.

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease characterized by the progressive loss of motor neurons, nerve cells that control the voluntary muscles. This leads to overall ...

Whole-body MRI (WB-MRI) may improve ALS diagnostic certainty. WB-MRI assesses muscle swelling (edema) as a marker for lower ...

Having resilience is so important to me that I’ve written several columns about it. I believe resilience — the ability to cope with and survive change — is a skill ALS patients should hone to navigate ...

Oral PrimeC for ALS significantly reduced toxic TDP-43 protein levels in a Phase 2b trial. PrimeC also slowed functional decline and extended survival by about 15 months. The treatment was well ...